Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
American Journal of Hematology|April 11, 2016
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patientsLisa Pieri, Patrizia Bonadonna, Chiara Elena, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Blood Advances|October 14, 2021
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemiaGiovanni Martinelli, Cristina Papayannidis, Alfonso Piciocchi, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
American Journal of Hematology|April 11, 2016
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patientsLisa Pieri, Patrizia Bonadonna, Chiara Elena, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Blood Advances|October 14, 2021
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemiaGiovanni Martinelli, Cristina Papayannidis, Alfonso Piciocchi, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Pageof 17